Last Updated : July 24, 2024
Details
Generic Name:
zanubrutinib
Project Status:
Not filed
Therapeutic Area:
Relapsed or refractory follicular lymphoma
Manufacturer:
BeiGene Canada ULC
Brand Name:
Brukinsa
Project Line:
Reimbursement Review
Project Number:
NS0037-000
Biosimilar:
No
Submission Type:
Non-submission
Fee Schedule:
N/A
Indications:
Zanubrutinib in combination with obinutuzumab
for the treatment of adult patients with relapsed or refractory grade 1, 2 or
3a follicular lymphoma (FL) who have received at least 2 prior systemic
therapies.
Recommendation Type:
Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission.
Last Updated : July 24, 2024